Rebound Or Fakeout? The 200-Day MA Holds The Key To The Next Big Move A discussion whether the rebound could sustain, the worst scenario and the potential target price for the S&P 500.
Celsius, Lucid And Signet Are Among Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio? Top performers last week: DGNX (108.29%), NEXT (25.07%), CELH (21.60%), SIG (21.08%), NFE (20.63%), MRP (16.61%), ARQT (16.35%), LCID (15.79%), CPRX (15.27%), STNE (14.20%). Are they in your portfolio?
What's Going On With Arcutis Biotherapeutics Stock Monday? Arcutis shares traded higher on Monday after Health Canada approved its Zoryve cream for the treatment of mild to moderate atopic dermatitis.
Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter.
Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains. The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025.
ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q2 2024 ARQT stock results show that Arcutis Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
7 Biotech Stocks to Keep on Your Clinical Radar Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs.
FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years FDA approved Arcutis Biotherapeutics' sNDA for Zoryve cream 0.15% for mild to moderate atopic dermatitis in patients aged six and older. Zoryve provides a steroid-free treatment option. Significant improvement in itch was observed within 24 hours of application.
